Nevertheless, taken together with recent reports that the effect of targeting CAFs may depend on tumour type and on the experimental systems that were used46,66, future studies should be performed to carefully examine the benefit of targeting CAF-derived IL-1β in breast cancer. The gene discussed is IL1B; the disease is neoplasm.